A Crucial Moment for Biotech in NYC
New York City’s world-class universities and hospitals create tremendous opportunity for growth of the biotech economy in coming years. However, in order to leverage our advantages, we must invest in human and physical capital; identify locations where clustering of businesses can take place; and work with other cities to push Washington to end the callous and short-sighted sequestration cuts to research and development.
As this excellent article notes, New York City’s biotech hub has indeed arrived at a crucial moment.
In 2007, I partnered with elected officials, community and labor leaders, civic groups and grassroots organizations to forge an agreement on an unprecedented rezoning of West Harlem, which laid the groundwork for future jobs and investment in New York City’s burgeoning biotech sector while striving to preserve the existing social and physical character of West Harlem.
That same year, my office contributed $500,000 to the groundbreaking Alexandria Center for Science and Technology on City-owned land. In just a few short years, that facility has already become a node for discovery and innovation on Manhattan’s East Side.
Other recent investments also promise to support a robust biotech ecosystem—from BioBAT, a 486,000-square-foot center for commercial bioscience at the Brooklyn Army Terminal, to the recently-opened New York Genome Center in Lower Manhattan.
Today, New York City is poised to compete with Boston and San Francisco for the next generation of biotech innovation and the well-paying jobs that accompany it. Robust community engagement and participation is a growth strategy that New York City must continue to embrace as we continue to evolve.















